Publication: Capturing Measures That Matter: The Potential Value of Digital Measures of Physical Behavior for Alzheimer’s Disease Drug Development
Authors: Shelby L. Bachman, Jennifer M. Blankenship, Michael Busa, Corinna Serviente, Kate Lyden, and Ieuan Clay Abstract Alzheimer's disease (AD) is a devastating neurodegenerative disease and the primary cause of dementia worldwide. Despite the magnitude of AD's impact on patients, caregivers, and society, nearly all AD clinical trials fail. A potential contributor to this high rate of failure is that established clinical outcome assessments fail to capture subtle clinical changes, entail high burden for patients and their caregivers, and ineffectively address the aspects of health deemed important by patients and their caregivers. AD progression is associated with widespread changes in physical behavior that have impacts on the ability to function independently, which is a meaningful aspect of health for patients with AD and important for diagnosis. However, established assessments of functional independence remain underutilized in…